Veracyte (VCYT) Stock Price, News & Analysis

Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $35.37 to $37.76
• 50-Day Range: $28.57 to $39.53
• 52-Week Range: $18.61 to $41.43
• Volume: 1.63 million shs
• Average Volume: 771,503 shs
• Market Capitalization: $2.79 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.00
• Consensus Rating: Moderate Buy

Veracyte Stock Analysis - MarketRank™

Veracyte scored higher than 91% of companies evaluated by MarketBeat, and ranked 193rd out of 973 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 8 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Veracyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 112.50%

Earnings Growth

Earnings for Veracyte are expected to grow by 112.50% in the coming year, from $0.16 to $0.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veracyte is -239.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veracyte is -239.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Veracyte has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.00% of the outstanding shares of Veracyte have been sold short.

Short Interest Ratio / Days to Cover

Veracyte has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veracyte does not currently pay a dividend.

Dividend Growth

Veracyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.02

Percentage of Shares Shorted

4.00% of the outstanding shares of Veracyte have been sold short.

Short Interest Ratio / Days to Cover

Veracyte has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.88

News Sentiment

Veracyte has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Veracyte this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

5 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $345,409.00 in company stock.

Percentage Held by Insiders

Only 1.30% of the stock of Veracyte is held by insiders.

VCYT Stock Analysis - Frequently Asked Questions

How have VCYT shares performed this year?

Veracyte's stock was trading at $27.51 on January 1st, 2024. Since then, VCYT shares have increased by 30.6% and is now trading at $35.94.
View the best growth stocks for 2024 here.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.16. The business's revenue for the quarter was up 28.6% on a year-over-year basis.

Does Veracyte have any subsidiaries?

The following companies are subsidiaries of Veracyte: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Who are Veracyte's major shareholders?

Top institutional investors of Veracyte include ARK Investment Management LLC (6.44%), Wellington Management Group LLP (5.46%), ArrowMark Colorado Holdings LLC (3.85%) and State Street Corp (3.76%). Insiders that own company stock include John Leite, Giulia C Kennedy, Bonnie H Anderson, Evan/ Fa Jones, Karin Eastham, John L Bishop, Jens Holstein and Muna Bhanji.
View institutional ownership trends.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/15/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:VCYT
• CUSIP: N/A
• CIK: 1384101
• Web: www.veracyte.com
• Phone: (650) 243-6300
• Fax: 650-243-6301
• Employees: 790
• Year Founded: 2006

Price Target and Rating

• Average Stock Price Target: $41.00
• High Stock Price Target: $50.00
• Low Stock Price Target: $26.00
• Potential Upside/Downside: +13.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 226.81
• P/E Growth: N/A
• Net Income: $-74,400,000.00
• Net Margins: -2.18%
• Pretax Margin: -1.92%
• Return on Equity: 3.02%
• Return on Assets: 2.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.08
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: $361.05 million
• Price / Sales: 7.79
• Cash Flow: $0.09 per share
• Price / Cash Flow: 425.91
• Book Value: $15.18 per share
• Price / Book: 2.39

Miscellaneous

• Outstanding Shares: 77,500,000
• Free Float: 76,493,000
• Market Cap: $2.81 billion
• Optionable: Optionable
• Beta: 1.67